



FOR IMMEDIATE RELEASE

For Further Information:

Rick Carlson
Chief Executive Officer
(952) 476-9093
rcarlson@prourocare.com

Jeff Elliott
Halliburton Investor Relations
(972) 458-8000
jelliott@halliburtonir.com

**ProUroCare Medical Announces Completion of Study by
Physician in Clinical Trial**

EDEN PRAIRIE, MN, March 18, 2009 – ProUroCare Medical Inc. (**OTCBB: PUMD**), announced today that the first physician at one of the major participating centers has completed his portion of the study for the ProUroScan™ prostate imaging system. The results from these clinical trials will be used in ProUroCare’s application to the Food and Drug Administration for 510(k) clearance of the ProUroScan system.

ProUroCare’s Chief Executive Officer Rick Carlson, stated, “We believe that the basic mapping and data maintenance claim, as defined in our proposed labeling claims with the FDA, accurately reflects the current needs of the market and the capabilities of the system. The center completing the study achieved results that exceeded those presented in our last peer reviewed article in the journal *Urology*, March 2008. This bodes well for the future of the ProUroScan technology. We applaud this physician and his staff for their commitment and diligent efforts in completing their portion of the clinical study.”

Overview of Clinical Study

The ProUroScan system will be regulated as a Class II device, which is typically cleared through a 510(k) application. The FDA protocol calls for a 40-patient clinical trial involving participation by four different physicians. In addition to the recently completed study, a second physician has already begun his patient trials, and two more are expected to begin their studies in the near future.

About ProUroCare Medical Inc.

ProUroCare Medical Inc. is a development stage company engaged in the business of developing for market innovative products for the detection and characterization of urological prostate disease. Currently, the Company’s primary focus is the ProUroScan prostate imaging system, which is now in clinical trials.



Safe Harbor Statement

This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of ProUroCare's future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause ProUroCare's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the ability of ProUroCare to find adequate financing to complete the development of its products; the high level of secured and unsecured debt incurred by ProUroCare; the dependence by ProUroCare on third parties for the development and manufacture of its products; and other risks and uncertainties detailed from time to time in ProUroCare's filings with the Securities and Exchange Commission including its most recently filed **Form 10-KSB and Form 10-Q**. ProUroCare undertakes no duty to update any of these forward-looking statements.